文献速递炎症性肠病

Upadacitinib治疗克罗恩病的真实世界多中心前瞻性研究

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-10

意大利IG-IBD开展的前瞻性多中心观察性UPGRADE-CD研究纳入391例经治克罗恩病患者,评估Upadacitinib的疗效与安全性。第12周临床缓解率51.2%,第24周54.7%,无新的安全信号。

要点

  • 经治CD患者中Upadacitinib第24周临床缓解率达54.7%
  • 基线活动性肠外表现者第24周65.7%完全缓解
  • 第24周停药率11.3%,无重大心血管或血栓事件

核心结论

  • Upadacitinib在经治克罗恩病患者中有效且耐受性良好,诱导获益维持至6个月,无新的安全信号。

研究设计与样本

  • 前瞻性、多中心、观察性研究,覆盖意大利38个中心,连续纳入经治CD患者启动Upadacitinib治疗。
  • 安全性分析纳入391例接受至少1剂的患者,疗效分析纳入323例。

主要发现

  • 第12周临床缓解率51.2%,第24周54.7%(p=0.07)。
  • 无激素临床应答从53.8%升至63.5%(p=0.09)。
  • 基线活动性肠外表现占39.9%,第24周65.7%完全缓解。
  • 基线HBI较高是未达缓解的最强预测因素。
  • 第24周停药率11.3%,其中治疗失败7.2%、不良事件3.1%;无重大心血管、血栓栓塞事件或恶性肿瘤。

关键数值与推荐

  • 临床应答定义为HBI下降≥3,临床缓解定义为HBI≤4。

临床怎么用

  • Upadacitinib可用于经治CD患者,包括合并活动性肠外表现者。
  • 治疗前基线HBI较高者需关注缓解率可能较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Upadacitinib is an oral selective JAK1 inhibitor approved for moderate-to-severe Crohn's disease (CD), but real-world prospective multicentre data in advanced therapy-experienced (AT-experienced) patients are limited. The UPGRADE-CD study evaluated its effectiveness and safety. METHODS: In this prospective, multicentre, observational study across 38 Italian centres, we enrolled consecutive AT-experienced CD patients initiating upadacitinib. Effectiveness was assessed at weeks 12 and 24, including clinical response (HBI reduction ≥ 3) and remission (HBI ≤ 4), steroid-free counterparts, biomarker normalisation, resolution of extraintestinal manifestations (EIMs) and endoscopic outcomes. Safety was assessed in all patients receiving ≥ 1 dose. RESULTS: A total of 391 patients were included in the safety analysis and 323 in the efficacy analysis; 48% had failed more than two advanced therapies. Clinical remission reached 51.2% at Week 12 and 54.7% at Week 24 (p = 0.07). Steroid-free clinical response rose from 53.8% to 63.5% (p = 0.09). Active EIMs, present in 39.9% at baseline, resolved completely in 65.7% by Week 24. Higher baseline HBI was the strongest predictor of failure to achieve remission. Discontinuation by Week 24 was 11.3%, mainly from treatment failure (7.2%) and adverse events (3.1%). No major cardiovascular, thromboembolic events or malignancies occurred. CONCLUSIONS: Upadacitinib was effective and well-tolerated in AT-experienced CD, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Barberio B, D'Amico F, Laterza L, et al. Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD). Aliment Pharmacol Ther. 2026. PMID: 42720163. doi:10.1111/apt.70970

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。